TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure
Status:
Recruiting
Trial end date:
2022-08-14
Target enrollment:
Participant gender:
Summary
TRANSFORM-HF is a large-scale, pragmatic, randomized, unblinded clinical effectiveness study
comparing torsemide versus furosemide as treatment for heart failure. Approximately 6,000
patients with heart failure will be enrolled. The primary objective of the TRANSFORM-HF study
is to compare the treatment strategy of torsemide versus furosemide on clinical outcomes over
12 months in patients with heart failure who are hospitalized.
Phase:
Phase 3
Details
Lead Sponsor:
Duke University
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) Yale University